Treatment of renal osteodystrophy

被引：1
作者：
Gal-Moscovici A. [1 ,2 ]
Sprague S.M. [2 ,4 ]
Lerma E.V. [3 ]
机构：
[1] Hadassah Hospital Medical Center, Hebrew University, Ein Keren, Jeruslaem
[2] Division of Nephrology and Hypertension, Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine, Evanston, IL
[3] Section of Nephrology, University of Illinois at Chicago, College of Medicine/Associates in Nephrology, Chicago, IL
[4] Evanston, IL 60201
来源：
Clinical Reviews in Bone and Mineral Metabolism | 2007年 / 5卷 / 1期
关键词：
Cinacalcet; Parathyroidectomy; Phosphate binders; Renal osteodystrophy; Vitamin D receptor agonist;
D O I：
10.1007/BF02736669
中图分类号：
学科分类号：
摘要：
Chronic kidney disease (CKD) is accompanied by disturbances in calcium, phosphate, vitamin D, and parathyroid hormone (PTH) homeostasis known to play an important role in the pathophysiology of renal osteodystrophy. Increased cardiovascular morbidity and mortality rate among CKD patients, correlates with these disturbances in bone and mineral metabolism and underscores the nephrologist's concern about the effectiveness of the present therapeutic approach. Treatment directed to normalize the calcium/phosphate, vitamin D and PTH abnormalities may adversely affect endothelial, vascular and bone cells activity. This article discusses the therapeutic approaches focuses for renal osteodystrophy. © Copyright 2007 by Humana Press Inc. All rights of any nature whatsoever reserved.
引用
收藏
页码：27 / 38
页数：11
相关论文
共 115 条
[101]  
Vadam M., Furuya Y., Sakiyama J., Et al., NPS R-568 halts or reverses osteoitis fibrosis in uremic rats, Kidney Int, 53, pp. 448-453, (1997)
[102]  
Goodman W.G., Fravo G.M., Goodkin D.A., Et al., A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism, Kidney Int, 58, pp. 436-445, (2000)
[103]  
Lindberg J.S., Moe S.M., Goodman W.G., Et al., Calcimimetic AMG 073 reduces parathyroid hormone and calcium X phosphate in secondary hyperparathyroidism, Kidney Int, 63, pp. 248-254, (2003)
[104]  
Drueke T.B., Cunningham J., Goodman W.G., Et al., Short term treatment of secondary hyperparathyroidism (SHPT) with calcimimetic agent AMG073, Am J Soc Nephrol, 12, (2001)
[105]  
De Francisco A.L.M., Surany M., Cunningham J., Et al., Oral cinacalcet HCl (AMG073) for the treatment of hemodialysis patients with secondary hyperparathyroidism, results of an European/Australian phase 3 study, J Am Soc Nephrol, 14, (2003)
[106]  
Brach G.A., Martin K.J., De Francisco A.L.M., Et al., Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis, N Engl J Med, 350, pp. 1520-1529, (2004)
[107]  
Lindberg J.S., Culleton B., Wong G., Et al., Phase 3 experience with cinacalcet HCl and hemodialysis and peritoneal dialysis patients with secondary hyperparathyroidism, J Am Soc Nephrol, 14, (2003)
[108]  
Moe S.M., Cunningham J., Bommer J., Et al., Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl, Nephrol Dial Transplant, 20, pp. 2186-2193, (2005)
[109]  
Yasunaga C., Nakamoto M., Matsuo K., Et al., Effects of parathroidectomy on the immune system and nutritional condition in chronic dialysis patients with secondary hyperparathyroidism, Am J Surg, 178, (1999)
[110]  
Garcia-Clanton C., Palomar R., Moreno A., Et al., Evolution of anemia of chronic renal failure after the treatment of hyperparathyroidism, Nephron, 74, (1996)
3456789101112